On Friday, Novo Nordisk announced in a company statement that it has once again applied to the US Food and Drug Administration (FDA) for permission to start marketing the weekly diabetes treatment Ozempic in a higher dosage.
In February, the FDA declined to start processing a previous application since the health authority lacked information on factors such as a new production facility before granting the necessary approvals. Instead, the FDA sent a Refusal to File Letter in March.
Already a subscriber? Log in.
Read the whole article
Get 14 days free access.
No credit card required.
Get full access for you and your coworkers.Start a free company trial today
Your trial for MedWatch has now started
With your free trial you get:
Full access to all locked articles on MedWatch.
Daily newsletter and ongoing top-newsletters. You can unsubscribe and subscribe to our newsletters anytime.
When your trial period expires
You will not be transferred to a paid subscription.
You will continue to receive our newsletters after the trial period expires. You can unsubscribe at the bottom of each newsletter.